Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics
Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast cancers, therefore a vital biomarker in its diagnosis, as well as a commonly used predictive factor for treatment and prognostic factor for survival in breast cancer.Pathologists are essential to